

Resistance to human β -defensins is common among oral treponemes

C. A. Brissette¹, L. G. Simonson³,
S. A. Lukehart^{1,2}

Departments of ¹Pathobiology and ²Medicine,
University of Washington, Seattle, WA, USA;
³Naval Institute for Dental and Biomedical
Research, Great Lakes, IL, USA

Brissette CA, Simonson LG, Lukehart SA. Resistance to human β -defensins is common among oral treponemes.

Oral Microbiol Immunol 2004; 19: 403–407. © Blackwell Munksgaard, 2004.

Background/aims: Oral treponemes are implicated in the pathogenesis of periodontal disease. We have previously shown that *Treponema denticola* ATCC type strains and strain GM-1 are resistant to killing by human β -defensins (h β D)-1 and -2. We hypothesize that resistance to β -defensins is a common feature of oral treponemes, which allows colonization and persistence in the oral cavity. In this study, we tested additional isolates of *T. denticola*, as well as six other species of treponemes, for resistance to h β D-1, -2 and -3. We also examined the four ATCC strains of *T. denticola* and strain GM-1 for resistance to h β D-3.

Methods: Resistance was determined by motility and Alamar Blue assays for metabolic activity.

Results: All *T. denticola* strains tested were resistant to h β D-1, -2 and -3, with the exception of strain Ambigua, which was sensitive to h β D-2 and -3. All other treponemes except *Treponema vincentii* were resistant to h β D-1. *Treponema pectinovorum* was sensitive to h β D-2, while *T. vincentii*, *T. pectinovorum* and *Treponema maltophilum* were sensitive to h β D-3. *Escherichia coli* was used as a control organism and was killed by all three defensins.

Conclusion: Resistance to the constitutively expressed h β D-1 may assist treponemes in initial colonization of epithelial surfaces, while resistance to the inducible h β D-2 and -3 would allow some treponemes to survive in active periodontal lesions.

Key words: *Treponema*; defensins; periodontal disease

Catherine A. Brissette, Harborview Medical Center, Box 359779, 325 Ninth Avenue, Seattle WA 98104, USA

E-mail: cbrisset@u.washington.edu

Accepted for publication August 2, 2004

Humans produce several antimicrobial peptides, including the α and β defensins and the cathelicidin LL-37. α -defensins HNP 1–4 are expressed by neutrophils, and α -defensins 5 and 6 are expressed by Paneth cells of the small intestine. β -defensins are epithelium-derived; four have been characterized to date. LL-37, the only human cathelicidin, is produced by both neutrophils and epithelium (35). There has been great interest in using synthetic antimicrobial peptides as an adjunct to traditional therapies for oral diseases (15, 30, 44), but naturally occurring antimicrobial peptides likely play a

role in protection from periodontal disease (1, 23). Severe periodontal disease is seen in patients with morbus Kostmann, an inherited neutrophil disorder, and is associated with a deficiency of antimicrobial peptides including LL-37 and α -defensins HNP 1–4 (36).

Both epithelial- and neutrophil-derived antimicrobial peptides from nonhuman mammals have proven effective against periodontal pathogens such as *Porphyromonas gingivalis*, *Prevotella intermedia*, *Actinobacillus actinomycetemcomitans*, *Eikenella corrodens*, and *Capnocytophaga* spp. *in vitro* (27–29). Recently, β -defensins

were demonstrated to have activity against *P. gingivalis*, actinomycetes, streptococci, and *Candida* species (17, 25, 33). β -defensins are found in saliva and gingival crevicular fluid, and are expressed by the oral epithelium, tongue, and salivary glands (3, 9, 10, 12, 13, 26, 37). Human β -defensin-1 is expressed constitutively in gingival tissues; h β D-2 and -3 are induced in response to some periodontal microorganisms and inflammatory stimuli (18–20).

Our previous studies indicate that *Treponema denticola* ATCC type strains and strain GM-1 are resistant to h β D-1 and -2 (6). However, there are more than 40

additional oral treponemal species, many uncultivated, and their sensitivities to β -defensins have not been determined (11). In this study we investigate the susceptibility of additional isolates of *T. denticola* and several species of oral treponemes to h β D-1, -2, and -3.

Material and methods

Bacterial culture

T. denticola strains ATCC 35405, 35404, 33521, 33520 and GM-1 were obtained from Pamela Braham (University of Washington, Seattle, WA) and maintained as previously described (2). *Escherichia coli* strain ML35 was obtained from ATCC (American Type Culture Collection, Rockville, MD) and maintained in Luria–Bertani medium at 37°C. All other *Treponema* species utilized in this study are listed in Table 1. *Treponema lecithinolyticum* and *Treponema maltophilum* were maintained in OMIZ-P4 (45) with the following additions: for *T. lecithinolyticum*, 100 mg/l asialofetuin, 2 g/l D-trehalose, 2 g/l L-rhamnose (Becton Dickinson and Company, Cockeysville, MD), 2 g/l D-sucrose; for both *T. lecithinolyticum* and *T. maltophilum*, 1% v/v yeast extract (Becton Dickinson and Company), 1% v/v neopeptone (Becton Dickinson and Company), and 1% heat-inactivated human serum. *Treponema medium*, *Treponema socranskii* and *Treponema vincentii* were maintained in NOS media as modified by Walker et al. (43). *Treponema pectinovorum* was maintained in GM-1 medium supplemented with 2% v/v heat-inactivated rabbit serum, 150 mM ACES buffer, 0.6% w/v D-galacturonic acid and 0.75% v/v yeast extract. Because defensin sensitivity may be affected by growth phase, growth curves for all oral treponeme species were established (data not shown), and testing was conducted with log phase organisms. All treponemes were grown anaerobically. Unless otherwise stated, all chemicals and reagents were from the Sigma Chemical Company (St. Louis, MO).

Defensin killing assay

Four-day log-phase cultures of *Treponema* species and log-phase cultures of *E. coli* were centrifuged at 10,000 \times g for 10 min at 20°C. Bacteria were washed once and resuspended in modified chemically defined medium (OMIZ-P4 without phenol red and sugars). 1×10^8 motile treponemes/ml were added to quadruplicate wells of a 96-well polypropylene plate

Table 1. Bacterial strains and sources

Bacterial species	Strain	Source
<i>Treponema denticola</i>	Ambigua	L. Simonson
<i>Treponema denticola</i>	T32A	L. Simonson
<i>Treponema denticola</i>	D65BR1	L. Simonson
<i>Treponema denticola</i>	7	L. Simonson
<i>Treponema medium</i>		ATCC 700293
<i>Treponema vincentii</i>		ATCC 33580
<i>Treponema lecithinolyticum</i>		ATCC 700332
<i>Treponema maltophilum</i>		ATCC 51940
<i>Treponema socranskii</i> ssp. <i>socranskii</i>		ATCC 35536
<i>Treponema pectinovorum</i>		ATCC 33768




Fig. 1. *T. denticola* ATCC type strains are resistant to killing by h β D-3. 1×10^8 mid-log phase treponemes/ml were incubated with 10 μ g/ml of h β D-3 for 4 h. A 1/10 vol of Alamar Blue was added and bacteria were incubated for an additional 20 h. Reduction of Alamar Blue indicates treponemal viability. Data represent the means (percent killing) and standard errors from four or more experiments. Similar results were shown by motility assay. Student's *t*-test assuming unequal variances was used to determine significance; ****P* < 0.001.




Fig. 2. Other *T. denticola* strains are resistant to killing by h β D-1, -2, and -3. 1×10^8 mid-log phase treponemes/ml were incubated with 10 μ g/ml of h β D-1, -2, or -3 for 4 h. A 1/10 vol of Alamar Blue was added and bacteria were incubated for an additional 20 h. Reduction of Alamar Blue indicates treponemal viability. Data represent the means (percent killing) and standard errors from four or more experiments. Similar results were shown by motility assay. Student's *t*-test assuming unequal variances was used to determine significance of killing compared to untreated bacteria; ****P* < 0.001.

(Corning Incorporated Life Sciences, Acton, MA) and incubated with 10 μ g/ml of h β D-1, -2 or -3 (Peptrotech, Rocky Hill, NJ) or 0.2% SDS (positive control for killing). Previously, we determined that *T. denticola* was insensitive to a range of

concentrations of h β D-1 and -2, up to 100 μ g/ml (6). Motility (% motile) was determined by dark-field microscopy. After 4 h of incubation at 37°C and 5% CO₂, a 1/10 vol. of Alamar Blue (Bio-source, Camarillo, CA) was added and

bacteria were incubated for an additional 20 h. The optical density for each well was read on a Dynatech colorimetric plate reader at 570 and 600 nm. Percent reduction of Alamar Blue was calculated according to manufacturer's instructions. Percent killing was determined by the formula:

$$\frac{(\% \text{ reduction in presence of peptide})}{(\% \text{ reduction in absence of peptide})} \times 100$$

As a control for h β D activity, *E. coli* ML35 was incubated in the same manner, and viability was determined by plate count. Student's *t*-test assuming unequal variances was used to determine significance. Previously, we demonstrated that the Alamar Blue assay for metabolic activity correlated with both motility of *T. denticola* as visualized by dark-field microscopy, and viability as determined by colony forming units on semisolid medium (6). Viability as measured by Alamar Blue reduction and treponemal motility correlate in both stationary and log phase growth ((6) and data not shown).

Results

T. denticola ATCC type strains are resistant to killing by h β D-3

Previously, we determined that *T. denticola* type strains ATCC 35404, 35405, 33520, 33521, as well as strain GM-1, are resistant to a range of concentrations of h β D-1 and -2, that no killing could be observed up to 24 h, and that resistance was present in both stationary and mid-log phase (6). To determine whether these strains are also resistant to h β D-3, *T. denticola* strains were incubated with h β D-3 and resistance was determined by motility and Alamar Blue assay. All four ATCC strains and strain G⁻¹ were resistant to h β D-3 under these assay conditions, whereas significant killing of *E. coli* occurred ($P < 0.001$, Fig. 1). h β D-3 concentrations as high as 230 μ g/ml had no effect on *T. denticola* viability (data not shown).

Other *T. denticola* strains are resistant to killing by h β D-1, -2, and -3

To determine whether resistance to β -defensins is common among more recent isolates of *T. denticola*, clinical isolates representing three serovars were tested for susceptibility to h β D-1, -2, and -3. Strains D65BR1, T32A, and 7 were resistant to h β D-1, -2 and -3 as determined by both Alamar Blue assay (Fig. 2) and motility determination (data not shown). Strain Ambigua demonstrated some susceptibil-

ity to h β D-2 and -3; whereas the level of killing was not significantly different than the control in the absence of peptide, it was considerably higher than any other *T. denticola* strains tested, on a par with the observed *E. coli* killing (Fig. 2). In the motility assay, Ambigua was significantly killed by h β D-3 ($P = 0.03$, data not shown). Data for all *T. denticola* strains tested are summarized in Table 2A.

Susceptibility of oral treponemes to killing by h β D-1, -2, and -3

Six oral treponeme species were tested in mid-log phase for susceptibility to h β D-1,

-2, and -3. As demonstrated in Fig. 3, only *T. vincentii* was killed by h β D-1 after 4 h ($P < 0.05$). *T. pectinovorum* was killed by h β D-2 ($P < 0.05$), while *T. vincentii*, *T. pectinovorum*, and *T. maltophilum* were killed by h β D-3 ($P < 0.01$, 0.05, 0.05, respectively). Many of the oral *Treponema* spp. are quite fastidious and do not remain viable in the absence of antimicrobial peptides for longer than a few hours, so we were unable to determine if extended incubation in the presence of β -defensins might demonstrate killing. Taken together, these results suggest that most oral treponemes are resistant to h β D-1 and -2, although three species of treponemes are

Table 2. Summary of treponemal susceptibility to h β D-1, -2, and -3

A	Serovar	h β D-1	h β D-2	h β D-3
35405	A	—	—	—
7	B	—	—	—
33521	B	—	—	—
GM-1	B-like	—	—	—
35404	C	—	—	—
33520	C	—	—	—
T32A	C	—	—	—
D65BR1	D	—	—	—
Ambigua	D	—	+/-	+/-

B	Phylogenetic group	h β D-1	h β D-2	h β D-3
<i>T. vincentii</i>	1	+	—	+
<i>T. medium</i>	1	—	—	—
<i>T. lecithinolyticum</i>	4	—	—	—
<i>T. maltophilum</i>	4	—	—	+
<i>T. socranskii</i>	6	—	—	—
<i>T. pectinovorum</i>	8	+/-	+	+

Data are summarized from Fig. 1–3. Some of the data on *T. denticola* ATCC 35405, 35404, 33520, 33520, and G⁻¹ were previously published (6). —, no killing. +, statistically significant killing ($P < 0.05$). +/-, killing not significant, but strong trend towards susceptibility.




Fig. 3. Susceptibility of oral treponemes to killing by h β D-1, -2, and -3. 1×10^8 mid-log phase treponemes/ml were incubated with 10 μ g/ml of h β D-1, -2, or -3 for 4 h. A 1/10 vol of Alamar Blue was added and bacteria were incubated for an additional 20 h. Reduction of Alamar Blue indicates treponemal viability. Data represent the means (percent killing) and standard errors from four or more experiments. Similar results were shown by motility assay. Student's *t*-test assuming unequal variances was used to determine significance; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

sensitive to hβD-3. *T. medium*, *T. lecinoliticum*, and *T. socranskii* were resistant to all three defensins, just like *T. denticola*. Data for all treponeme strains tested are summarized in Table 2B.

Discussion

Oral treponemes are closely linked with periodontal disease, and make up the bulk of the microflora present in diseased sites (21, 22). To thrive in this inflammatory environment, oral *Treponema* must have evolved mechanisms for avoiding the host's innate immune response. Recent studies have elegantly demonstrated the importance of antimicrobial peptides such as β-defensins *in vivo* (7, 31, 32, 34, 38). We have previously shown that *T. denticola* ATCC strains 35405, 35404, 33520, 33521, and strain GM-1 are resistant to a range of concentrations of hβD-1 and -2. We now demonstrate that these five *T. denticola* strains are also resistant to hβD-3. Resistance to hβD 1-3 is common both among ATCC strains and more recent isolates. Sensitivity to a given hβD does not appear to correlate with *T. denticola* serovar, as only one of nine isolates demonstrated any sensitivity to β-defensins (Strain Ambigua, Fig. 2).

Treponema have been placed into 10 phylogenetic groups based on 16S rRNA analysis; seven of these groups have cultivatable members, and all groups have representative species or clones present in the mouth (11). We examined the sensitivity of several treponema to β-defensins. Only *T. vincentii*, one of seven species tested, is sensitive to hβD-1. Only *T. peccinovorum* is sensitive to hβD-2, and three species tested are sensitive to hβD-3. Interestingly, hβD-1 is the least potent human β-defensin, while hβD-3 has the broadest spectrum of antimicrobial activity (16, 17, 42), which correlates with our findings. Phylogenetic grouping did not appear to correlate with sensitivity or resistance: *T. medium* and *T. vincentii* are closely related Group 1 treponemes, but only *T. vincentii* demonstrates sensitivity to hβD-1 and -3. *T. maltophilum* and *T. lecinoliticum* are Group 4 treponemes, but only *T. maltophilum* is sensitive to hβD-3.

The mechanism of β-defensin antimicrobial activity is unclear, but may involve membrane disruption and interference with negatively charged macromolecules such as DNA (14). Thus, the slow growth and unique membrane composition of treponemes may help explain the resistance of *T. denticola* and other oral treponemes to

human β-defensins. However, other spirochetes have demonstrated sensitivity to cathelicidins and neutrophil-derived defensins from humans and rabbits, suggesting another mechanism of resistance is present (4, 5, 8, 24, 39). In addition, we have previously demonstrated that resistance to β-defensins is evident for *T. denticola* in both stationary and mid-log phase, and no killing was observed with incubation times of up to 24 h; this suggests the slow growth rate of oral treponemes is not responsible for their resistance (6). We have previously shown that proteolytic activity of *T. denticola* is not responsible for resistance to β-defensins (6). An intriguing possibility for a resistance mechanism arises from the newly completed *T. denticola* genome, which shows the presence of 84 efflux pump-related genes (40). Efflux of antimicrobial peptides has been demonstrated to account for the resistance of another mucosal pathogen, *Neisseria gonorrhoeae* (41). We are further exploring this mechanism in *T. denticola*.

In conclusion, most oral *Treponema* are resistant to human β-defensins. Resistance to the constitutively expressed hβD-1 may enable treponemes to associate closely with the gingival epithelium and to establish themselves early in the periodontal lesion. Resistance to the inducible hβD-2 or -3 may dictate which treponemes are prevalent in the inflammatory environment of the active periodontal lesion.

Acknowledgments

C.A.B. was supported by NIDCR Training Grant DE07023. This work was supported by Public Health Service Grant DE015354 and University of Washington Research Royalty Fund proposal no. 2681.

References

1. Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, McCray PB Jr, et al. Expression of beta-defensins in gingival health and in periodontal disease. *J Oral Pathol Med* 2004; **33**: 278–85.
2. Blakemore RP, Canale-Parola E. Arginine catabolism by *Treponema denticola*. *J Bacteriol* 1976; **128**: 616–622.
3. Bonass WA, High AS, Owen PJ, Devine DA. Expression of beta-defensin genes by human salivary glands. *Oral Microbiol Immunol* 1999; **14**: 371–374.
4. Borenstein LA, Ganz T, Sell S, Lehrer RI, Miller JN. Contribution of rabbit leukocyte defensins to the host response in experimental syphilis. *Infect Immun* 1991; **59**: 1368–1377.
5. Borenstein LA, Selsted ME, Lehrer RI, Miller JN. Antimicrobial activity of rabbit leukocyte defensins against *Treponema pallidum* subsp. *pallidum*. *Infect Immun* 1991; **59**: 1359–1367.
6. Brissette CA, Lukehart SA. *Treponema denticola* is resistant to human beta-defensins. *Infect Immun* 2002; **70**: 3982–3984.
7. Ceccarelli AV, Cole AM, Park AK, Tahk S, Yoshioka D, Ganz T. Therapeutic effect of a pig-derived peptide antibiotic on porcine wound infections. *Comp Med* 2001; **51**: 75–79.
8. Cox DL, Sun Y, Liu H, Lehrer RI, Shafer WM. Susceptibility of *Treponema pallidum* to host-derived antimicrobial peptides. *Peptides* 2003; **24**: 1741–1746.
9. Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. Localized antimicrobial peptide expression in human gingiva. *J Periodontol Res* 2001; **36**: 285–294.
10. Dale BA, Krisanaprakornkit S. Defensin antimicrobial peptides in the oral cavity. *J Oral Pathol Med* 2001; **30**: 321–327.
11. Dewhirst FE, Tamer MA, Ericson RE, Lau CN, Levanos VA, Boches SK, et al. The diversity of periodontal spirochetes by 16S rRNA analysis. *Oral Microbiol Immunol* 2000; **15**: 196–202.
12. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. *Eur J Oral Sci* 2002; **110**: 121–124.
13. Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S. Expression profile of human defensins and antimicrobial proteins in oral tissues. *J Oral Pathol Med* 2001; **30**: 154–158.
14. Ganz T. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol* 2003; **3**: 710–720.
15. Genco CA, Maloy WL, Kari UP, Motley M. Antimicrobial activity of magainin analogues against anaerobic oral pathogens. *Int J Antimicrob Agents* 2003; **21**: 75–78.
16. Harder J, Bartels J, Christophers E, Schroder J-M. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. *J Biol Chem* 2001; **276**: 5707–5713.
17. Joly S, Maze C, McCray PB Jr, Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. *J Clin Microbiol* 2004; **42**: 1024–1029.
18. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA. Inducible expression of human beta-defensin-2 by *Fusobacterium nucleatum* in oral epithelial cells. Multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. *Infect Immun* 2000; **68**: 2907–2915.
19. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. *Infect Immun* 1998; **66**: 4222–4228.
20. Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. *J Invest Dermatol* 2002; **118**: 275–281.

21. Loesche WJ. The spirochetes. In: Newman MG, Nisengard RJ, eds. Oral Microbiology and Immunology. Philadelphia: Saunders, 1988: 228–236.
22. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: Diagnosis and treatment. Clin Microbiol Rev 2001; **14**: 727–752.
23. Lu Q, Jin L, Darveau RP, Samaranayake LP. Expression of human beta-defensins-1 and -2 peptides in unresolved chronic periodontitis. J Periodontal Res 2004; **39**: 221–227.
24. Lusitani D, Malawista SE, Montgomery RR. *Borrelia burgdorferi* are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J Infect Dis 2002; **185**: 797–804.
25. Maisetta G, Batoni G, Esin S, Luperini F, Pardini M, Bottai D, et al. Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother 2003; **47**: 3349–3351.
26. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; **67**: 2740–2745.
27. Miyasaki KT, Bodeau AL, Ganz T, Selsted ME, Lehrer RI. *In vitro* sensitivity of oral, Gram-negative, facultative bacteria to the bactericidal activity of human neutrophil defensins. Infect Immun 1990; **58**: 3934–3940.
28. Miyasaki KT, Bodeau AL, Selsted ME, Ganz T, Lehrer RI. Killing of oral, Gram-negative, facultative bacteria by the rabbit defensin, NP-1. Oral Microbiol Immunol 1990; **5**: 315–319.
29. Miyasaki KT, Iofel R, Oren A, Huynh T, Lehrer RI. Killing of *Fusobacterium nucleatum*, *Porphyromonas gingivalis* and *Prevotella intermedia* by protegrins. J Periodontal Res 1998; **33**: 91–98.
30. Miyasaki KT, Lehrer RI. Beta-sheet antibiotic peptides as potential dental therapeutics. Int J Antimicrob Agents 1998; **9**: 269–280.
31. Morrison G, Kilanowski F, Davidson D, Dorin J. Characterization of the mouse beta-defensin-1, Defb1, mutant mouse model. Infect Immun 2002; **70**: 3053–3060.
32. Moser C, Weiner DJ, Lysenko E, Bals R, Weiser JN, Wilson JM. Beta-defensin-1 contributes to pulmonary innate immunity in mice. Infect Immun 2002; **70**: 3068–3072.
33. Nishimura E, Eto A, Kato M, Hashizume S, Imai S, Nisizawa T, et al. Oral streptococci exhibit diverse susceptibility to human beta-defensin-2: antimicrobial effects of h β D-2 on oral streptococci. Curr Microbiol 2004; **48**: 85–87.
34. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; **414**: 454–457.
35. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; **62**: 17ii–21.
36. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002; **360**: 1144–1149.
37. Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA. Expression of the antimicrobial peptide, human beta-defensin-1, in duct cells of minor salivary glands and detection in saliva. J Dent Res 2000; **79**: 1669–1674.
38. Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003; **422**: 522–526.
39. Sambri V, Marangoni A, Giacani L, Gennaro R, Murgia R, Cevenini R, et al. Comparative *in vitro* activity of five cathelicidin-derived synthetic peptides against *Leptospira*, *Borrelia* and *Treponema pallidum*. J Antimicrob Chemother 2002; **50**: 895–902.
40. Seshadri R, Myers GS, Tettelin H, Eisen JA, Heidelberg JF, Dodson RJ, et al. Comparison of the genome of the oral pathogen *Treponema denticola* with other spirochete genomes. Proc Natl Acad Sci U S A 2004; **101**: 5646–5651.
41. Shafer WM, Qu X, Waring AJ, Lehrer RI. Modulation of *Neisseria gonorrhoeae* susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A 1998; **95**: 1829–1833.
42. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998; **95**: 14961–14966.
43. Walker SG, Ebersole JL, Holt SC. Identification, isolation, and characterization of the 42-kilodalton major outer membrane protein (MompA) from *Treponema pectinovorum* ATCC 33768. J Bacteriol 1997; **179**: 6441–6447.
44. Weinberg A, Krisanaprakornkit S, Dale BA. Epithelial antimicrobial peptides: Review and significance for oral applications. Crit Rev Oral Biol Med 1998; **9**: 399–414.
45. Wyss C. Growth of *Porphyromonas gingivalis*, *Treponema denticola*, *T. pectinovorum*, *T. socranskii*, and *T. vincentii* in a chemically defined medium. J Clin Microbiol 1992; **30**: 2225–2229.

This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.